Publications by authors named "L Grossar"
Objectives: To review the current indications for liver transplantation (LT) in cirrhosis, including evolving criteria for hepatocellular carcinoma (HCC) and other malignancies, how donor organ allocation is established, and to address challenges of long-term complications post-transplantation.
Methods: A comprehensive review of the literature was conducted to evaluate advancements in LT indications, pretransplant evaluation protocols, organ allocation strategies, and management approaches for long-term post-transplant complications.
Results: Liver transplantation remains the definitive treatment for cirrhosis and offers substantial survival benefits for patients with early-stage HCC.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a highly lethal cancer with a low 5-year survival rate, highlighting the need for effective monitoring and prognosis.
- A systematic review analyzed 3,904 studies to investigate if N-glycomics can predict HCC risk and survival in adults with chronic liver disease, ultimately including 30 studies in the analysis.
- The findings suggest that changes in N-glycans, particularly the Mac-2 binding protein glycosylation isomer (M2BPGi), are valuable indicators for predicting HCC development and patient prognosis.
Background & Aims: The goal of treatment in autoimmune hepatitis (AIH) is induction of remission to prevent the development of liver fibrosis, cirrhosis, and its related complications. Various definitions of treatment response and remission have been used. The International Autoimmune Hepatitis Group (IAIHG) recently defined consensus criteria for treatment response.
View Article and Find Full Text PDFSystematic review: Glycomics as diagnostic markers for hepatocellular carcinoma.
Aliment Pharmacol Ther
January 2024
Article Synopsis
- Hepatocellular carcinoma (HCC) is a serious liver cancer with high mortality; early diagnosis is key to improving treatment options.
- A comprehensive review of scientific literature identified serum N-glycomics, particularly alterations like increased fucosylation and branching, as promising diagnostic markers for HCC, showing strong potential with AUCs between 0.92-0.97.
- More rigorous study designs and larger sample sizes are necessary to validate these findings before N-glycomics can be widely used in clinical settings for HCC diagnosis.